The C1orf159 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 human cell line, designed for functional investigation of the C1orf159 gene. This pooled population carries disruptions in C1orf159, enabling loss-of-function studies without clonal selection artifacts. The polyclonal format preserves genetic heterogeneity while ensuring robust target-gene disruption, suitable for high-throughput screening and phenotypic assays. These knockout cells facilitate exploration of C1orf159??s role, as its molecular function remains uncharacterized.
HAP1 cells are a near-haploid human cell line derived from KBM-7 chronic myeloid leukemia cells, with fibroblastoid morphology and adherent growth. The haploid karyotype simplifies genetic analysis, requiring only one allele edit for complete disruption, reducing complexity versus diploid models. HAP1 is a cornerstone for functional genomics, used in CRISPR screens, drug target validation, and interaction proteomics due to genetic tractability. This knockout model benefits from the haploid background, enabling efficient interrogation of gene function across a polyclonal population.
C1orf159 is a predicted protein-coding gene with no established molecular function or signaling role. Its upstream regulators, downstream targets, and interacting partners are unknown, and it lacks disease associations. The protein product is computationally predicted but unvalidated. CRISPR/Cas9-mediated knockout in HAP1 allows dissection of C1orf159??s contribution to phenotypes such as proliferation, apoptosis, and migration, generating hypotheses for its mechanistic involvement. The absence of known interactors highlights this model??s value for de novo pathway discovery.
The near-haploid nature of HAP1 cells provides a powerful context for studying uncharacterized genes like C1orf159. With only one functional allele, knockout effects are more penetrant, reducing signal-to-noise in functional assays. This model enables systematic evaluation of C1orf159-dependent phenotypes under controlled conditions. The polyclonal approach mitigates off-target concerns by averaging clone-specific effects, ensuring phenotypes are generally attributable to the intended disruption. High-content imaging or flow cytometry can quantitatively assess C1orf159??s impact on cell behavior.
Researchers can apply C1orf159 Knockout HAP1 Polyclonal Cells in gene function discovery, protein interaction mapping via co-IP and mass spectrometry, and drug target identification. Compatible assays include Western blotting (once antibodies are available), RT-qPCR for transcript changes, Sanger sequencing for genotyping, immunofluorescence for localization, and flow cytometry for cell cycle or apoptosis. Functional assays measuring proliferation, apoptosis, and migration provide direct phenotypic readouts. Contact Ascent Research for further details or technical support.
